Submit Deal

CALIDI BIOTHERAPEUTICS

Summary

Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 641 M

Avg. Deal Size£ 321 M

Market Context

Senior Management

Allan Camaisa
CEO and Chairman
Tony Kalajian
CFO

Sort

09 Jan 2023|United States|Pharmaceuticals

Target: CALIDI BIOTHERAPEUTICS

Bidder: FIRST LIGHT ACQUISITION GROUP

5 Service Providers

2 Target | 3 Bidder

34 Dealmakers

1 Target | 34 Bidder

£ 277 M

Value

02 Feb 2023|United States|Pharmaceuticals

Target: CALIDI BIOTHERAPEUTICS

Bidder: EDOC ACQUISITION CORP

8 Service Providers

4 Target | 4 Bidder

11 Dealmakers

3 Target | 8 Bidder

£ 364 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy